174 related articles for article (PubMed ID: 23480385)
1. MCP-1 in psoriatic patients: effect of biological therapy.
Lembo S; Capasso R; Balato A; Cirillo T; Flora F; Zappia V; Balato N; Ingrosso D; Ayala F
J Dermatolog Treat; 2014 Feb; 25(1):83-6. PubMed ID: 23480385
[TBL] [Abstract][Full Text] [Related]
2. Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: a retrospective investigation of 146 psoriasis patients.
Hoffmann JH; Knoop C; Enk AH; Hadaschik EN
J Dermatol Sci; 2014 Dec; 76(3):180-5. PubMed ID: 25306295
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
4. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
[TBL] [Abstract][Full Text] [Related]
5. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study.
Kyriakou A; Patsatsi A; Sotiriadis D
J Dermatolog Treat; 2013 Jun; 24(3):162-8. PubMed ID: 22136334
[TBL] [Abstract][Full Text] [Related]
6. The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study.
Julià M; Guilabert A; Lozano F; Suarez-Casasús B; Moreno N; Carrascosa JM; Ferrándiz C; Pedrosa E; Alsina-Gibert M; Mascaró JM
JAMA Dermatol; 2013 Sep; 149(9):1033-9. PubMed ID: 24048425
[TBL] [Abstract][Full Text] [Related]
7. Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment.
Van L; Modi SV; Yang DJ; Hsu S
Arch Dermatol; 2008 Jun; 144(6):804-6. PubMed ID: 18559778
[No Abstract] [Full Text] [Related]
8. TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis.
Murdaca G; Gulli R; Spanò F; Lantieri F; Burlando M; Parodi A; Mandich P; Puppo F
J Invest Dermatol; 2014 Oct; 134(10):2503-2509. PubMed ID: 24594669
[TBL] [Abstract][Full Text] [Related]
9. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
Montesu MA; Addis GM; Satta R; Cottoni F
G Ital Dermatol Venereol; 2011 Aug; 146(4):273-81. PubMed ID: 21785393
[TBL] [Abstract][Full Text] [Related]
10. Effect of biologic therapies targeting tumour necrosis factor-α on cutaneous mesenchymal stem cells in psoriasis.
Campanati A; Orciani M; Gorbi S; Regoli F; Di Primio R; Offidani A
Br J Dermatol; 2012 Jul; 167(1):68-76. PubMed ID: 22356229
[TBL] [Abstract][Full Text] [Related]
11. Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study.
Di Lernia V; Ricci C; Lallas A; Ficarelli E
J Dermatolog Treat; 2014 Feb; 25(1):73-4. PubMed ID: 23621374
[TBL] [Abstract][Full Text] [Related]
12. Development of MGUS in psoriatic patients: a possible undiagnosed event during anti-TNF-α-treatment.
Prignano F; Pescitelli L; Ricceri F; Ermini A; Lotti T
J Eur Acad Dermatol Venereol; 2012 Nov; 26(11):1444-8. PubMed ID: 21834947
[TBL] [Abstract][Full Text] [Related]
13. [Biological treatment of psoriasis and psoriatic arthritis].
Kragballe K; Deleuran B
Ugeskr Laeger; 2008 Jun; 170(24):2148-50. PubMed ID: 18565300
[TBL] [Abstract][Full Text] [Related]
14. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
15. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
Collamer AN; Battafarano DF
Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
[TBL] [Abstract][Full Text] [Related]
16. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
[TBL] [Abstract][Full Text] [Related]
17. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
[TBL] [Abstract][Full Text] [Related]
18. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis.
Chandran V; Shen H; Pollock RA; Pellett FJ; Carty A; Cook RJ; Gladman DD
J Rheumatol; 2013 Jun; 40(6):866-71. PubMed ID: 23637322
[TBL] [Abstract][Full Text] [Related]
19. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
Cozzani E; Burlando M; Parodi A
G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
